ID
BCRX icon

Integral Derivatives’s BioCryst Pharmaceuticals BCRX Stock Holding History

Integral Derivatives’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,709
Closed -$81K – 1310
2013
Q4 		$81K Buy
+10,709
New +$67.8K ﹤0.01% 1424

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Integral Derivatives's BCRX Position: Q1 2014 in Review

Integral Derivatives sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2014, closing a stake of 10,709 shares — an estimated $81K sold.

Integral Derivatives first reported a position in BCRX in Q4 2013 and held it in 1 quarter. The position peaked at $81K in Q4 2013. 88 funds tracked by Wall St. Rank hold BCRX as of Q1 2014.

  • Integral Derivatives reported no remaining BioCryst Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Integral Derivatives sold 10,709 BioCryst Pharmaceuticals shares in Q1 2014, an estimated $81K.
  • Integral Derivatives first reported a position in BioCryst Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Integral Derivatives's BioCryst Pharmaceuticals position peaked at $81K in Q4 2013.
  • 88 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2014.

Based on Integral Derivatives's 13F filing for Q1 2014, filed 2 May 2014.